a positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria阳性血清嗜碱细胞组胺释放试验是一个标记为ciclosporin-responsiveness自发慢性荨麻疹患者.pdfVIP

Iqbal et al. Clinical and Translational Allergy 2012, 2:19 /content/2/1/19 BRIEF COMMUNICATION Open Access A positive serum basophil histamine release assay is a marker for ciclosporin-responsiveness in patients with chronic spontaneous urticaria 1 1 2 2 1* Kamran Iqbal , Kapil Bhargava , Per Stahl Skov , Sidsel Falkencrone and Clive EH Grattan Abstract The electronic records of 398 patients with chronic spontaneous urticaria (CSU) who had had a serum basophil histamine release assay (BHRA) performed as a marker of functional autoantibodies were audited. The BHRA was positive in 105 patients (26.4%). Fifty eight were treated with ciclosporin because they were H1 anti-histamine unresponsive. CSU patients with a positive BHRA were more likely to respond clinically (P0.001) and to have raised thyroid autoantibodies (P0.02) than those with a negative BHRA. The BHRA offers a useful predictive biomarker for a good response of H1 antihistamine-unresponsive CSU patients to ciclosporin. Keywords: Ciclosporin, Chronic urticaria, Basophil histamine release assay Findings starting dose of ciclosporin was 4 mg/kg/d and the usual Functional factors including histamine-releasing auto- duration of treatment was between 3 and 4 months. antibodies have been identified by the BHRA in the sera Patients with other patterns of chronic urticaria includ- of 20–30% of patients with CSU [1-3]. CSU patients with ing inducible urticarias (physical, cholinergic and other a positive BHRA also have a higher incidence of thyroid types), angio-oedema without weals and urticarial vascu- an